These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 29044634)

  • 1. Rituximab for the treatment of type B insulin resistance syndrome: a case report and review of the literature.
    Iseri K; Iyoda M; Shikida Y; Inokuchi T; Morikawa T; Hara N; Hirano T; Shibata T
    Diabet Med; 2017 Dec; 34(12):1788-1791. PubMed ID: 29044634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case report: Successful combination therapy with double-filtration plasmapheresis and rituximab under the condition of the use of a sensor-augmented pump for type B insulin resistance syndrome.
    Osanami A; Kanda M; Sato T; Akazawa C; Baba S; Komatsu H; Murase K; Yamashita T; Yano T
    Front Endocrinol (Lausanne); 2022; 13():997296. PubMed ID: 36157458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment of type B insulin resistance with rituximab.
    Manikas ED; Isaac I; Semple RK; Malek R; Führer D; Moeller LC
    J Clin Endocrinol Metab; 2015 May; 100(5):1719-22. PubMed ID: 25675382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Management of Insulin Autoimmune Syndrome with Rituximab and Continuous Glucose Monitoring.
    Saxon DR; McDermott MT; Michels AW
    J Clin Endocrinol Metab; 2016 May; 101(5):1931-4. PubMed ID: 26982011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetic Ketoacidosis Without Diabetes.
    Willard D; Upadhyay J; Kim C; Steenkamp D
    J Clin Endocrinol Metab; 2016 Nov; 101(11):3870-3873. PubMed ID: 27636019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Saibokuto as a Possible Therapy for Type B Insulin Resistance Syndrome: The Disappearance of Anti-insulin Receptor Antibody and a Marked Amelioration of Glycemic Control by Saibokuto Treatment.
    Kawasaki F; Anno T; Takai M; Irie S; Kaneto H; Kaku K; Okimoto N
    Intern Med; 2018 Aug; 57(16):2359-2363. PubMed ID: 29526960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
    Stasi R; Stipa E; Del Poeta G; Amadori S; Newland AC; Provan D
    Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of the current use of rituximab in autoimmune diseases.
    Gürcan HM; Keskin DB; Stern JN; Nitzberg MA; Shekhani H; Ahmed AR
    Int Immunopharmacol; 2009 Jan; 9(1):10-25. PubMed ID: 19000786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful Treatment of ANCA-Associated Vasculitis in the Setting of Common Variable Immunodeficiency Using Rituximab.
    Hill F; Yonkof J; Chaitanya Arudra SK; Thomas J; Altorok N
    Am J Ther; 2016; 23(5):e1239-45. PubMed ID: 26291596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type B insulin resistance syndrome with diabetic ketoacidosis.
    Joung KH; Kim HJ; Ku BJ
    Acta Diabetol; 2012 Feb; 49(1):81-2. PubMed ID: 21387198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highly efficacious, long-term, triglyceride lowering with rituximab therapy in a patient with autoimmune hypertriglyceridemia.
    Béliard S; Di Filippo M; Kaplanski G; Valéro R
    J Clin Lipidol; 2018; 12(4):883-887. PubMed ID: 29784574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
    Zaja F; Iacona I; Masolini P; Russo D; Sperotto A; Prosdocimo S; Patriarca F; de Vita S; Regazzi M; Baccarani M; Fanin R
    Haematologica; 2002 Feb; 87(2):189-95. PubMed ID: 11836170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-Mediated Extreme Insulin Resistance: A Report of Three Cases.
    Kim HN; Fesseha B; Anzaldi L; Tsao A; Galiatsatos P; Sidhaye A
    Am J Med; 2018 Jan; 131(1):102-106. PubMed ID: 28822702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful remission of type B insulin resistance syndrome without rituximab in an elderly male.
    Concepción-Zavaleta MJ; Ildefonso-Najarro SP; Plasencia-Dueñas EA; Quispe-Flores MA; Armas-Flórez CD; Luna-Victorio LE
    Endocrinol Diabetes Metab Case Rep; 2020 Oct; 2020():. PubMed ID: 33434167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002-2004).
    Scheinberg M; Hamerschlak N; Kutner JM; Ribeiro AA; Ferreira E; Goldenberg J; Kiss MH; Chahade WH
    Clin Exp Rheumatol; 2006; 24(1):65-9. PubMed ID: 16539821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Favorable outcome of Epstein-Barr virus-associated B-cell lymphoproliferative disorder complicated by immunoglobulin G4-related disease treated with rituximab-based therapy: a case report.
    Ueda K; Ikeda K; Ogawa K; Sukegawa M; Sano T; Kimura S; Suzuki O; Hashimoto Y; Takeishi Y
    J Med Case Rep; 2016 Aug; 10(1):236. PubMed ID: 27557810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conventional induction and maintenance treatment of Antineutrophil cytoplasmic antibodies-associated vasculitis - still of value for our patients?
    Tesar V; Hruskova Z
    Expert Opin Pharmacother; 2015; 16(11):1683-702. PubMed ID: 26149512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type B insulin resistance syndrome associated with connective tissue disease and psoriasis.
    Łebkowska A; Krentowska A; Adamska A; Lipińska D; Piasecka B; Kowal-Bielecka O; Górska M; Semple RK; Kowalska I
    Endocrinol Diabetes Metab Case Rep; 2020 Aug; 2020():. PubMed ID: 32755965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type B insulin resistance syndrome with Scleroderma successfully treated with multiple immune suppressants after eradication of Helicobacter pylori infection: a case report.
    Yang GQ; Li YJ; Dou JT; Wang BA; Lu JM; Mu YM
    BMC Endocr Disord; 2016 May; 16(1):20. PubMed ID: 27142369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
    Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
    Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.